PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
3 hedge funds and large institutions have $3.59K invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 7 closing their positions.
0.21% less ownership
Funds ownership: 0.22% → 0.01% (-0.21%)
67% less funds holding
Funds holding: 9 → 3 (-6)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
96% less capital invested
Capital invested by funds: $99.1K → $3.59K (-$95.5K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$39 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Personalized Indexing Management
Oakland,
California
|
-$18.7K |
| 2 |
Mariner
Overland Park,
Kansas
|
-$18.4K |
| 3 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$14.7K |
| 4 |
SG
StoneX Group
New York
|
-$13.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$12.1K |
PHXM Hedge Fund Activity: Q3 2023 in Review
3 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q3 2023, worth a combined $3.59K — down 96% from $99.1K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PHXM and 1 opened new positions — a net loss of 6 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $39. The largest seller was Vanguard Personalized Indexing Management, exiting entirely with an estimated $18.7K sold.
- 3 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q3 2023, down from 9 in Q2 2023.
- Funds reported $3.59K of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q3 2023, down 96% quarter-over-quarter.
- 1 fund opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q3 2023 and 7 closed out, a net change of -6 holders.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q3 2023 was UBS Group, an estimated $39 added.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q3 2023 was Vanguard Personalized Indexing Management, an estimated $18.7K sold.
Based on aggregated 13F filings for Q3 2023.